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Abstract Continuous Pharmaceutical Manufacturing (CPM) emerges as a ground-breaking technology which can invigorate the global pharmaceutical industry by sustainably fostering its agility and the affordability of 
healthcare for large populations. Continuous production methods feature numerous significant technical advantages, which 
however need be ensured by robust, scaleable chemistry, systematic process design and efficient Process Analytical Technology (PAT) 
for control. Quality by Design (QbD) must be achieved by a relentless pursuit of efficiency in energy and solvent use, but above all the 
business case for a product must be strong enough to cover both synthesis and process R&D against competition. Remarkable 
corporate investments in production-scale CPM facilities illustrate the value and promise of this paradigm. This paper focuses on 
applications of process systems engineering methodologies (flowsheet modelling and simulation) toward evaluating the technical 
efficiency, environmental impact and economic viability of two continuous processes. Original final upstream separation results for 
ibuprofen and recent ones for plantwide CPM economics are discussed. 
Continuous pharmaceutical 
process engineering and economics
Investigating technical efficiency, environmental impact 
and economic viability
INTRODUCTION
Pharmaceutical processes are broadly distinguished in 
batch (the overwhelming majority) and continuous (a 
growing minority): in either case, a process comprises a 
primary (upstream) and a secondary (downstream) part: 
the first addresses production of the Active Pharmaceutical 
Ingredient (API or Drug Substance, DS), while the latter 
focuses on mixing the API with excipients to manufacture the 
final marketed formulation (Drug Product, DP). 
The incentive for technically sound and economically 
viable CPM (1) depends on each business case, but also 
on technical advances in organic synthesis, multiphase flow 
units and process automation (2). The business aspect has 
paramount importance for deciding if a CPM process should 
even be evaluated (3). The economic viability is determined 
using several factors: the total manufacturing cost comprising 
capital (CapEx) and operating (OpEx) expenditures, the 
product selling price, marketing costs, and often product 
and/or technology licensing costs (4).
Batch organic synthesis of API molecules at laboratory 
and production scale is an arduous procedure, in which 
long sequences of separate reactions are performed in 
large reactors, with purification steps conducted between 
successive stages. This normally effective procedure is also 
extremely wasteful: the E-factor (waste-to-product ratio) is as 
high as 25-100 for APIs, indicating that 25-100 kg of waste are 
generated for every 1 kg of API produced (petrochemical 
industries have E << 1). Reducing the manufacturing cost is 
possible via fewer reactions, fewer separations and more 
efficient unit operations. Disruptive microreactor technology 
enables previously unattainable syntheses, which are 
now possible via dramatic intensification (much higher 
concentration, pressure, temperature) and/or drastic 
reaction time reduction (flash chemistry), in which hazardous 
reactions can be safely performed and highly unstable 
intermediates can be used in flow (5-6). Precise reaction 
time control (< 1s) yields higher selectivity, economising 
on unit size (lower CapEx) and materials (lower OpEx). 
Microreactors facilitate rapid and efficient scaling up of 
flow syntheses, unleashing CPM potential due to several key 
advantages (7). Several continuous flow microreactors can 
accommodate catalyst immobilisation, gas handling and 
multiphase reactions, ensuring process intensification due 
to their high mixing efficiency, effective heat removal and 
low process inventories (8-10). Common pharmaceutical 
syntheses include hydrogenations, nitrations, fluorinations, 
oxidations and organometallic reactions. 
The most important contributions which hold the promise to 
revolutionise the global pharmaceutical industry by facilitating 
the advent of CPM processes can thus be summarised in 
synthetic chemistry and process engineering, as:
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downstream processing is critical toward final dosage 
formation. Successful separation design must satisfy 
technical, regulatory but also environmental constraints, 
and the E-factor (ratio of API mass produced over total 
waste generated) is a convenient metric for evaluating 
how benign a process is.
Systematic unit operation modelling and simulation is very 
useful in designing and operating efficient 
separations: one of the several choices 
available is Liquid-Liquid Extraction (LLE), 
here explored in the context of ibuprofen 
CPM. Judicious selection of LLE solvents is 
key from a technical (efficiency) as well as 
an environmental (waste) viewpoint. For 
LLE design, stream F20 is assumed to be 
a binary (water-methanol) mixture which 
carries several solutes, and multicomponent 
thermodynamics (the UNIFAC method) 
have been used to compute effluent 
compositions upon solvent addition and 
phase separation at ambient (25 °C) as 
well as effluent (65 °C) temperature, to 
facilitate comparisons (18). Thermodynamic 
equilibrium between the aqueous and 
the organic phase is taken to be rapidly 
established in the unit, with crystallisation 
and precipitation phenomena negligible. 
The API distribution in effluent (organic/O, 
water/W) streams relies on assuming that 
the ibuprofen partition coefficient is equal 
to the ratio of corresponding solubilities in each phase. 
Technical (recovery) and environmental (E-factor) metrics 
for two solvents n-hexane and toluene are depicted in 
Figure 2. 
Increasing solvent feed is technically and environmentally 
detrimental, inducing lower recoveries and higher E-factors. 
- New, robust and more efficient chemical pathways are 
discovered and demonstrated for many APIs (5, 6, 11, 12).
- New miniaturised, multi-purpose reactors are developed 
and effective for a wide spectrum of conditions (8-10).
- New miniaturised separators are integrated in several 
pilot- and production-scale plant demonstrations (13-14).
Moreover, plantwide process modelling and simulation are 
instrumental toward CPM design, optimisation and control.
CONTINUOUS FLOW SYNTHESES
A rapidly growing body of literature details the quest for 
organic synthesis routes to replace batch with CPM processes. 
Continuous synthesis studies illustrate the production of 
ibuprofen (15), artemisinin (16) and 6-quinolone (17), and 
an extensive review covers a wide range of APIs (6). Process 
modelling, simulation (18-19) and optimisation (20) are key in 
CPM process analysis.
The flowsheet presented in Figure 1 considers a series of 3 
plug flow reactors (PFRs) toward producing ibuprofen (15). 
Isobutylbenzene (IBB) is mixed with propanoic acid and neat 
triflic acid (TfOH): the mixture enters the first reactor (150 °C), 
where IBB undergoes Friedel–Crafts acylation to produce 
a ketone (2). The outlet stream is cooled (0 °C) and then 
reacts with a cold (0 °C) solution of diacetoxyiodobenzene, 
PhI(OAc)2, in a mixture of trimethyl orthoformate (TMOF) 
and methanol (MeOH). The combined stream is fed to the 
second reactor (50 °C), where intermediate 2 undergoes 
PhI(OAc)2-mediated 1,2-aryl migration to produce an ester 
(3). The outlet stream is mixed with a methanol-water KOH 
solution and fed into the third reactor, where 3 undergoes 
base hydrolysis and is converted to the salt form of the API, 
K-ibuprofen.
ENVIRONMENTALLY BENIGN, EFFICIENT SEPARATIONS
Efficient continuous separations which can achieve high API 
recovery and low waste generation are essential for CPM. 
Reactor effluent streams often carry large excess reagent 
quantities for recycling and by-products for elimination. 
Ensuring that a high-purity API stream can be fed to 
Figure 2. Solvent use and environmental efficiency in the 
continuous ibuprofen process: (a) n-hexane, (b) toluene.
Figure 1. A continuous pharmaceutical process for ibuprofen (15, 19).
30 Chimica Oggi - Chemistry Today - vol. 33(6) November/December 2015
but to this day very few peer-reviewed publications 
have quantitatively evaluated the projected economic 
performance benefits. Envisaging that the promise of higher 
yields and selectivities will result in lower capital (CapEx) and 
operating (OpEx) costs as a result of continuous operation 
is plausible, but very few comparative evaluations of 
options have appeared. Roberge et al. (21) published a 
technoeconomic analysis of process alternatives for an 
annual capacity of 700 kg, identifying clear economic 
benefits (albeit without analysing the entire process, from raw 
materials to final product formulation). 
Schaber et al. (22) investigated the economic impact of 
operating an integrated CPM plant using an organic key 
intermediate (KI) and three organic reactions to derive 
the API, toward subsequent tablet formation, at an annual 
blockbuster drug production scale (2000 tons) and for several 
design parameters. The batch process has 
been evaluated for a set of four key CPM 
process variants (roller compaction/RC or 
direct tablet formation/DTF, with/without 
recycle). Three pivotal sensitivity variables 
(Key Intermediate/KI cost, 100-3000 USD/kg; 
production yield, ±10% vs. batch; tablet API 
load, 10 and 50 wt%) are employed for each 
variant, indicating a strong incentive for CPM 
implementation. Process flow diagrams for 
both pharmaceutical processes considered 
are illustrated in Figures 3 and 4, respectively. 
Seifert et al. (23) conducted an economic 
analysis of modular CPM in comparison to 
multi-product batch manufacturing plants, 
identifying that the former results in a 30% Net 
Present Value (NPV) increase over the latter: 
a further 35% NPV increase was obtained 
under the assumption that construction can 
be completed within one year.
The summary of CapEx, OpEx and total cost 
comparisons for all CPM cases considered 
by Schaber et al. (2011) is presented in 
Figure 5. The highest production cost 
reduction is obtained for a switch from 
batch to CPM with recycle (R) and tablet 
formation (TF), options; the alternative 
technology of roller compaction (RC) is also 
advantageous, but not in all cases without a 
recycle stream. Depending on KI production 
cost, total (CapEx+OpEx) cost savings range 
between 9-40% when batch and CPM yields 
coincide, but increase considerably (19-
44%) if the latter exceeds the former. Total 
cost savings remain noteworthy even for 
a CPM yield lower than the corresponding 
batch, due to the enormous CapEx 
savings achieved when using smaller, 
cheaper units. OpEx savings are due to 
lower labour and water/solvent costs (61% 
and 21%, respectively), but they illustrate 
higher KI price sensitivity. Another detailed 
technoeconomic analysis for ibuprofen 
and artemisinin further corroborates the 
strong incentive for CPM processes due 
to the remarkable cost savings attainable 
by continuous flow synthesis and efficient 
separations (24).
Hexane is superior to toluene in terms of LLE operability, due 
to a wider immiscibility window at low solvent feed ratios; it 
also achieves higher, less wasteful API recovery than toluene 
in the entire solvent feed range at ambient temperature. 
Nevertheless, the trend is reversed for the higher (PFR3 
effluent) temperature (65 °C), in which toluene is clearly more 
advantageous, as it offers consistently higher and marginally 
less wasteful API recovery, as long as phase immiscibility is 
ensured: the most technically efficient and environmentally 
benign LLE operation is achieved for ratios below 1 (0.75).
COST SAVINGS AND ECONOMIC BENEFITS
Numerous research studies highlight the incontrovertible 
technical advantages of CPM over batch processes, 
Figure 3. Process flow diagram for batch pharmaceutical manufacturing of an API (22).
Figure 4. Process flow diagram for continuous pharmaceutical manufacturing of an 
API (22). 
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7. Kockmann, N. et al., 
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of single-channel 
microreactors: from 
process development to 
industrial production”, 
Chem. Eng. J. 167(2-3): 
718-726 (2011).
8. Losey, M.W. et al., 
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multiphase packed-bed 
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of mass transfer and 
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Commun., 189(12): 1611-
1628 (2002).
10. Hartman, R. et al., 
“Deciding whether to go 
with the flow: evaluating 
CONCLUSIONS
The remarkable benefits of continuous over traditional 
batch processes for manufacturing APIs and organic 
intermediates are enormous and clearly documented, 
as the gradual adoption and industrial implementation 
of CPM concepts can result in significant technical as 
well as economic gains: CapEx savings are attainable 
via fewer unit operations and smaller footprint required, 
while OpEx savings emerge due to increased productivity 
(higher yield and selectivity), reduced materials, labour 
and waste. Microreactors improve heat and mass transfer 
rates spectacularly, enabling reaction intensification 
under reliable control. First-principles process modelling, 
simulation and optimisation (18-20) are pivotal enabling 
technologies toward rapid evaluation of process (flowsheet 
and unit operation topology) and operation (solvent 
selection) alternatives, and critical in accelerating R&D 
by systematic design of reactors and separators which 
demonstrably achieve optimal performance. Finally, this 
methodology can seamlessly accommodate detailed 
and comprehensive economic analyses (21-24) toward 
comparison with existing or potential batch counterparts, 
to investigate a priori the economic viability of CPM 
processes. 
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